These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study). Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjänen K, Smith JS. Gynecol Oncol; 2012 Apr; 125(1):175-80. PubMed ID: 22233689 [Abstract] [Full Text] [Related]
18. Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany. Iftner T, Becker S, Neis KJ, Castanon A, Iftner A, Holz B, Staebler A, Henes M, Rall K, Haedicke J, von Weyhern CH, Clad A, Brucker S, Sasieni P. J Clin Microbiol; 2015 Aug; 53(8):2509-16. PubMed ID: 26019212 [Abstract] [Full Text] [Related]